OptiNose
Oslo
About OptiNose
OptiNose develops nasal drug delivery technologies and novel combination drug/device therapies. The drug delivery technologies are based upon a unique and patent-protected principal "Bi-Directional Delivery" which allows drugs to be more efficiently delivered to the nasal cavity. By applying its drug delivery technology, most of the dose is deposited beyond the nasal valve in the upper posterior two-thirds of the nasal cavity, unlike traditional devices. The OptiNose delivery devices have high dose reproducibility and avoid drug deposition to the lungs. In summary, technology fulfills the ideal requirements for nasal drug delivery. Clinical trials have shown that devices can provide a faster onset of action, greater effect with a lower dose, and reduced side effects. The company has offices in Norway and the UK.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $50K – $100K
- Total funding: $560.4M
- Funding stage: M&A
- Last round: Post-IPO Equity (May 2024)
- Ticker: nasdaq:OPTN
- Website: optinose.com
- Phone: 267-364-3500
Industries & Categories
Biotechnology, Medical Device, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/optinose-13111 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.